Neurotech International Ltd’s Post

MST Financial has initiated research coverage on Neurotech International Ltd, assigning a valuation of $0.60. The MST Healthcare team, led by the highly regarded Senior Analyst Andrew Goodsall and Roy Taouk, highlights the company's current discount compared to its peers at a similar stage of development. The report also emphasises the market opportunities for NTI164 across the four clinical indications: autism, PANDAS/PANS, Rett Syndrome, and cerebral palsy. Read the full Report here: https://lnkd.in/gbseGvvq #NTI #Neurotech #MSTFinancial #HealthcareInvesting #BiotechResearch #NTI164 #ClinicalDevelopment #AutismResearch #PANDAS #RettSyndrome #CerebralPalsy #MarketOpportunities

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics